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The study aims to determine if the nonpneumatic antishock garment (NASG), a first aid compression device, decreases severe
adverse outcomes from nonatonic obstetric haemorrhage. Women with nonatonic aetiologies (434), blood loss > 1000mL, and
signs of shock were eligible. Women received standard care during the preintervention phase (226) and standard care plus
application of the garment in the NASG phase (208). Blood loss and extreme adverse outcomes (EAO-mortality and severe
morbidity) were measured. Women who used the NASG had more estimated blood loss on admission. Mean measured blood
loss was 370mL in the preintervention phase and 258mL in the NASG phase (P < 0.0001). EAO decreased with use of the garment
(2.9% versus 4.4%, (OR 0.65, 95% CI 0.24–1.76)). In conclusion, using the NASG improved maternal outcomes despite the worse
condition on study entry. These findings should be tested in larger studies.
1. Introduction
Obstetric haemorrhage is the most common cause of
maternal mortality in the developing world [1]. In Egypt,
postpartum haemorrhage is the most frequent cause of
maternal mortality, constituting 33.4% ofmaternal mortality
[2]. Advances in the prevention and management of atonic
postpartum haemorrhage include new uterotonics such as
misoprostol, new administration technologies for established
uterotonics, such as oxytocin in Uniject, balloon compres-
sion devices, and uterine compression sutures [3]. However,
these advances do not benefit women with nonatonic
aetiologies. Previous estimates considered uterine atony to
be responsible for the majority of postpartum haemorrhage
mortality [4]. In other studies of severe haemorrhage,
nonatonic aetiologies were found to be more common than
expected [5].
The nonpneumatic antishock garment (NASG) (Zoex
Corporation, Ashland, Ore, USA) is a neoprene and Velcro
lower-body first aid pressure device for hypovolaemic shock
made up of nine horizontal segments: three per leg (ankle,
calf, and thigh), one for the pelvis, and a larger segment
with a small foam compression ball for the abdomen. This
device reverses shock by decreasing the transmural pressure
and radius of the blood vessels in the lower body, thus
decreasing blood flow to the abdomen and lower body and
redirecting blood to the core organs. When a woman is
experiencing obstetric haemorrhage, this device can restore
her consciousness, pulse, and blood pressure, and it can
buy her time to receive definitive therapy [6]. The NASG is
relatively low cost at $170 USD per garment which can be
used approximately 40 times.
The NASG is uniquely applicable as a first aid device in
settings where delays in management are common. It also
allows complete access to the perineal area enabling vaginal
procedures without unfastening the garment and has an
easily opened abdominal segment enabling surgery while the
rest of the garment remains closed.
We have previously published the outcomes of a pilot
study in Egypt (n = 364) [5], an interim analyses of a small
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(n = 169) study at one facility in Nigeria [7] and a larger
study in Egypt (n = 990) [8]. This is a subgroup analysis of
the latter Egypt study which examines women with obstetric
haemorrhage and shock due to nonatonic aetiologies treated
with standard protocol versus nonatonic aetiologies treated
with standard protocol plus NASG.
2. Methods
In this study, 434 women were recruited from the emergency
admissions of two referral hospitals in Egypt; Assiut Univer-
sity Women’s Health Centre (13500 deliveries annually) and
El Galaa Teaching Hospital in Cairo (20000 deliveries annu-
ally). Both facilities receive referrals from home deliveries
and lower level facilities, and both are staffed by consulting
obstetricians and residents.
2.1. Settings and Participants. This study was conducted
from June 2006 to May 2008. Women were eligible regardless
if they began haemorrhaging outside the facility and were
transferred in or began haemorrhaging in the facility.
Included in this analysis were women with obstetric haem-
orrhage and shock due to any of the following aetiolo-
gies: ectopic gestation, trophoblastic disease of pregnancy,
placenta praevia, accreta or abruption, ruptured uterus, or
vaginal or cervical lacerations. All women had an estimated
blood loss > 1000mL, a pulse >100 beats per minute, or
systolic blood pressure (SBP) < 100mmHg on study admis-
sion. Clinician data collectors were trained on estimation of
concealed blood using the patient’s vital signs and symptoms
as indicators [9–11]. Estimation of revealed blood loss was
done using visual estimation and questioning of the patient.
The following conditions were contraindications to NASG
use and study exclusion: heart disease, pulmonary hyperten-
sion, a viable foetus in utero (e.g., some womenwith placenta
previa), and the presence of bleeding above the diaphragm.
The 434 women who had nonatonic haemorrhage aetio-
logies represent 44% of the total women included in the
larger study. Of those, 226 women were in the preinterven-
tion phase and 208 in the NASG phase. In the preinter-
vention phase, women were treated following standardized
evidence-based protocols that were prepared and approved
by the Egyptian Ministry of Health and Population [12].
In the NASG phase, 208 women were treated with the
standardized protocol plus application of the NASG.
Data was collected by staff in the facilities who were
trained on the standardized protocol, blood collection and
measurement, NASG use, and completion of data collection
forms. The volume of external blood loss was calculated
using a plastic blood collection drape (BRASSS-V Fixable
DrapeMadurai, India) that is snugly tied around the patient’s
waist and the collection bag is opened underneath the
woman. Blood loss suctioned or mopped with gauze or
towels during surgery was also measured and recorded.
2.2. Informed Consent. The study protocol was approved by
the University of California, San Francisco (UCSF) Commit-
tee on Human Research(CHR) (approval number H6899-
23524) and given ethical clearance by the Institutional
Review Boards of Assiut University Faculty of Medicine and
El Galaa Teaching Hospital, Cairo. In the preintervention
phase women gave informed consent to use their data.
Women in the intervention phase provided written informed
consent for the NASG and the use of their data. A US Federal
waiver of consent/authorization for minimal risk research
was obtained (45 CFR 46, 45 CFR 164.512) so that women
who were unconscious or confused at study entry were
enrolled and treatment was begun, but their data would only
be used if they gave informed consent after they regained
normal sensorium or if a relative gave consent on their
behalf.
2.3. Clinical Protocols. Following enrolment in the study,
women’s vital signs and blood loss were monitored while
the aetiology of the haemorrhage was identified and resus-
citation and treatment initiated. The women remained in
the study until vital signs had stabilized (SBP > 100, pulse
< 100) for a minimum of two hours and blood loss had
decreased to approximately 25–50mL per hour. Standard
haemorrhage/shock protocols at these facilities included:
administration of crystalloid intravenous fluids (≥1500mL
in the first hour), vaginal procedures, and provision of blood
transfusions and/or surgery as necessary. The NASG was left
completely in place during vaginal procedures. If laparotomy
was required, abdominal and pelvic segments were opened
immediately prior to making the incision and then replaced
as soon as the surgery was completed.
2.4. Outcomes. The primary outcome was extreme adverse
outcomes which include mortality and severe morbidity.
Morbidities were defined as organ system dysfunctions
related to severe obstetric hemorrhage and included: acute
respiratory distress syndrome (impairment of respiratory
function needing ventilation, oxygen supplementation, or
decreased physical activity level as compared to pre-
pregnancy), cerebral impairment (seizures, unconscious-
ness, or cognitive/motor loss), renal failure (creatinine >
1.5mg/dL or increased >1.0mg/dL above baseline, oliguria;
<120mL output in 4-hour intervals), and heart failure
(impairment of cardiac function according to New York
Heart Disease Classification) [13]. The secondary outcomes
were cumulative blood loss measured hourly after study
admission with the calibrated drape and morbidity and
mortality as individual variables.
2.5. Severity of Condition. The indicator of the severity of
the woman’s condition at study entry was mean arterial
pressure (MAP = [2∗diastolic blood pressure + systolic
blood pressure]/3) on study admission. Women with MAP
< 60mmHg were considered to be in more severe shock.
2.6. Data Collection. Hospital residents and nurses were
trained in the standardized protocol for management of
obstetric haemorrhage and shock, blood collection and
measurement, and completion of data collection forms. Prior
to the intervention phase, the staff was trained to use the
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NASG. All data were collected by the clinicians as they cared
for or immediately after caring for the patient in shock. All
data collection forms were reviewed by Egyptian Principal
Investigators and quality control was conducted regularly
during each study phase to resolve any disagreement or
inconsistency. Forms were sent electronically via a datafax
system (Clinical DataFax Systems Inc., ON, Canada) to
statisticians at the University of California, San Francisco
(UCSF) to be entered and analysed.
2.7. Statistical Analysis. Participants’ demographic charac-
teristics, condition on study entry, and treatment received in
the two study phases were compared using t-tests (assuming
unequal variances in the two phase populations) and chi-
square tests of independence. Fisher’s exact tests were used
for small cell sizes. Relative risks (RR) and 95% confidence
intervals were computed for the primary outcome, EAOs,
and for the secondary outcomes, mortality and severe
morbidity. Meanmeasured volume of blood loss in the drape
was compared across phases with t-tests.
3. Results
3.1. Baseline Characteristics. Women in the two study phases
were comparable regarding demographic characteristics and
duration of gestation. In the preintervention phase, there
were more women with placenta praevia (P = 0.014). In
the NASG phase, there were more women with vaginal or
cervical lacerations (P = 0.001) (see Table 1).
3.2. Condition on Study Entry. Women in the NASG phase
had significantly more estimated revealed and concealed
blood loss (Table 1). In addition, more women in the
NASG phase were in severe condition (MAP < 60mmHg)
upon study entry: 24.5% as compared to 15.6% in the
preintervention phase.
3.3. Treatment. Treatment variables (Table 2) show signif-
icantly fewer women in the NASG phase receiving either
≥1500mL crystalloid fluids or a blood transfusion in the first
hour (P < 0.001). By the end of the study admission, there
was no difference in the proportion of women who received
a blood transfusion.
3.4. Outcomes. Mean measured blood loss was significantly
lower in the NASG phase (P < 0.001). There weremore EAOs
in the preintervention phase although the difference was not
statistically significant. More women died in the NASG phase
while fewer women experienced severe morbidities; neither
were statistically significant (Table 3). Use of the NASG did
not confer any significant increase in the side effects that were
investigated, in fact there was significantly less nausea and
vomiting in the NASG phase (Table 4).
4. Discussion
4.1. Main Findings. The study results agree with previous
research that the NASG is useful for patients with obstetric
haemorrhage of nonatonic aetiologies. This study found the
device to be safe with no side effects. The effect of NASG
on the combined variable, EAO, and on severe morbidity
for women with nonatonic aetiologies confirms previous
reports of the benefit of NASG for all obstetric haemorrhage
aetiologies [9]. This is a promising finding given the fact that
women with these aetiologies will often need surgery, which
in many low-resource countries may not be feasible or may
be delayed due to personnel or logistic barriers. The higher
mortality in the NASG phase may be because of the worse
condition of women on study entry. However, this finding
is based on a sample size too small to draw meaningful
conclusions; it may be due to chance.
There were some limitations in the study. The first
limitation relates to the before-after nonrandomized design.
This may allow subjective selection of eligible cases by the
physicians. However, as the conditions of patients on study
entry in the NASG phase were worse, this is unlikely. Some
cases of obstetric haemorrhage at the facilities may not
have been enrolled, as some providers did not participate
in the study, but such missed cases would have been very
small in number. Further, hospital level statistics for both
sites showed that no mortality or severe morbidity was
missed, so it is unlikely that the effectiveness of the NASG is
over-estimated.
The results regarding blood loss confirm the previous
findings that the NASG reduces blood loss in obstetric
haemorrhage [5]. The effect on revealed blood loss reported
in this study was 113 cc difference, which may not be
clinically significant. However, this may partially explain
the beneficial effect of the NASG on patient outcomes. On
the other hand, this positive effect on the general outlook
of the patients may have a negative effect on the speed
of resuscitation. The fact that women in the NASG phase
received less IV fluids and blood in the first hour may be
explained by complacence in response to the improvement
in the general conditions as a result of the device. Physicians
may have been in less haste to infuse fluids and give blood
after seeing the beneficial effect of the NASG on the vital
signs, level of consciousness, and decreased blood loss. This
has serious implications for training on the introduction of
the NASG. Providing inadequate resuscitation or delaying
management may adversely affect outcomes for women in
the NASG.
The lack of statistical significance of the difference
between EAO during the two phases might be due to a
lack of power of the subanalysis of nonatonic aetiologies.
The sample size calculation was done to power the full
study, which included all obstetric haemorrhage aetiologies,
to detect differences in the outcomes. The power calculation
conducted with Epi Info Version 6 showed that the study
would need to include 2584 women in each arm to have 80%
power and 95% confidence to detect a 1.5% difference in
EAOs. Another possibility would be the worse condition on
admission in the NASG group. A third explanation may be
the less timely use of resuscitation received by women in the
NASG phase. This question remains largely unanswered and
requires a study that is powered for these aetiologies and in
which treatment would begin rapidly in both phases.
4 ISRN Obstetrics and Gynecology
Table 1: Demographics, diagnoses, and condition on entry to study, by phase (N = 434).
Pre (N = 226) Post (N = 208) Statistical test
Demographics
Mean age (SD) (n = 433) 29.2 29.0 t-test, t = 0.47
SD = 6.5 SD = 6.3 P = 0.639
Mean parity (SD) (n = 433) 2.4 2.5 t-test, t = −0.42
SD = 2.2 SD = 2.2 P = 0.678
Mean duration of pregnancy (SD) (n = 388)∗ 24.4 25.5 t-test, t = −0.76
SD = 14.0 SD = 14.5 P = 0.447
Primary definitive diagnosis, n (%)‡
Ectopic pregnancy (n) 35.4% (80) 34.1% (71)
χ2 = 0.076
P = 0.782
Molar pregnancy (n) 3.1% (7) 4.3% (9)
χ2 = 0.461
P = 0.497
Placenta praevia (n) 10.2% (23) 3.9% (8)
χ2 = 6.545
P = 0.014√
Placenta accreta (n) 2.2% (5) 3.4% (7)
χ2 = 0.536
P = 0.563√
Abruption of placenta (n) 26.1% (59) 25.0% (52)
χ2 = 0.070
P = 0.792
Ruptured uterus (n) 13.3% (30) 8.7% (18)
χ2 = 2.351
P = 0.125
Vaginal/cervical lacerations (n) 9.7% (22) 20.7% (43)
χ2 = 10.178
P = 0.001
Condition on study entry
Mean-estimated revealed blood loss in mL ‖ (SD) (n = 218)† 1006 1219 t-test, t = −3.061
SD = 512 SD = 514 P = 0.003
Mean-estimated concealed blood loss in mL (SD) (n = 290)† 1198 1324 t-test, t = −2.765
SD = 391.1 SD = 378.4 P = 0.006
Women with MAP < 60 % (n) (n = 432)∗∗ 15.6% (35) 24.5% (51) χ
2 = 5.546
P = 0.020
∗
Does not include preterm pregnancies. ‡Woman could have multiple diagnoses, percentages add to more than 100%.
√
Fisher’s exact values reported when
variables have any cell less than 10. ‖Only for women with external blood loss at study admission. †Women can have both revealed and concealed blood loss.
∗∗Includes women with nonpalpable blood pressure.
Table 2: Treatment, by phase (N = 434).
Pre (N = 226) Post (N = 208) Statistical test
Women who received ≥1500mL of IV fluids in the first
hour from study admission % (n)Φ
93.4% (211) 64.9% (135)
χ2 = 54.268
P < 0.0001
Women who received a blood transfusion some time
after study admission % (n)
100% (226) 99.5% (207)
χ2 = 1.089
P = 0.479√
Women who received a blood transfusion in the 1st
hour from study admission % (n)
96.5% (218) 86.5% (180)
χ2 = 14.017
P < 0.0001
√
Φ
The protocol asked for 1500mL to be administered in the first hour of resuscitation, however, in some cases only 1000mL were administered in the first
hour, while the remaining 500mL were administered in the second hour.
√
Fisher’s exact test was used.
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Table 3: Outcomes, by phase (N = 434).
Pre (N = 226) Post (N = 208) Statistical test
Mean blood loss as measured in the drape (mL), (SD) (n = 155)¶ 370.4 257.7 t-test, t = 4.394
SD = 174.1 SD = 140.8 P < 0.0001
Mortality, % (n) (n = 434) 0.4% (1) 1.9% (4) RR = 4.35
95% CI = 0.49–38.57
Severe morbidity, % (n) (n = 429)∗ 4.0% (9) 1.0% (2) RR = 0.25
95% CI = 0.05–1.12
Extreme adverse outcome (EAO)∗∗, % (n) (n = 434) 4.4% (10) 2.9% (6) RR = 0.65
95% CI = 0.24 – 1.76
¶
For cases in whom the blood collection drape was used and there were data for blood loss. Women with a primary diagnosis of abruption were excluded
from this analysis due to the nature of the blood loss of this aetiology-pooled internal blood loss and clots captured in the drape after delivery of the placenta
which should not be included in the blood loss calculation. §Only for women with definitive diagnoses of abruption of placenta, ruptured uterus, placenta
previa, and placenta accrete. ∗Only for women who survived ∗∗EAO = mortality or morbidity.
Table 4: Potential side effects of NASG treatment, by phase (N = 433).
Pre (N = 225) Post (N = 208) RR and 95% CI
Any side effects, % (n) 64.4% (145) 67.8% (141)
RR = 1.05
95% CI = 0.92–1.20
Respiratory symptoms/dyspnoea, % (n) 7.1% (16) 8.2% (17)
RR = 1.15
95% CI = 0.60–2.22
Reduced urine output, % (n) 9.8% (22) 10.1% (21)
RR = 1.03
95% CI = 0.59–1.82
Nausea, % (n) 28.0% (63) 19.2% (40)
RR = 0.69
95% CI = 0.48–0.97
Vomiting, % (n) 29.3% (66) 19.7% (41)
RR = 0.67
95% CI = 0.48–0.95
Abdominal pain, % (n) 60.9% (137) 60.6% (126)
RR = 0.99
95% CI = 0.85–1.16
5. Conclusion
The NASG may be a promising first aid device in the
management of obstetric haemorrhage due to nonatonic
aetiologies in tertiary level facilities in low-resource settings.
The promise of the NASG can only be realized along with
rapid implementation of shock and haemorrhage protocols.
In the absence of other advances to manage these conditions,
it is worthwhile to study the effectiveness of the NASG for
nonatonic aetiologies in a study powered to demonstrate
significant differences in outcomes.
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